Does Rallies show 13F holders for ATAI?

Yes. Rallies tracks hedge fund and 13F ownership data for ATAI, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ATAI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ATAI. It does not provide personalized investment advice.

ATAI (AtaiBeckley Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

AtaiBeckley Inc. Common Stock (ATAI) is a publicly traded Healthcare sector company. As of May 21, 2026, ATAI trades at $4.14 with a market cap of $1.53B and a P/E ratio of -4.84. ATAI moved +3.41% today. Year to date, ATAI is +5.68%; over the trailing twelve months it is +99.51%. Its 52-week range spans $1.03 to $6.75. Analyst consensus is strong buy with an average price target of $14.90. Rallies surfaces ATAI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ATAI stock?

Hedge funds tracked by Rallies that own ATAI include Centerbook Partners and Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for AtaiBeckley Inc. Common Stock.

ATAI Key Metrics

Key financial metrics for ATAI
Metric	Value
Price	$4.14
Market Cap	$1.53B
P/E Ratio	-4.84
EPS	$-0.83
Dividend Yield	0.00%
52-Week High	$6.75
52-Week Low	$1.03
Volume	4.53K
Avg Volume	0
Revenue (TTM)	$3.02M
Net Income	$-154.30M
Gross Margin	0.00%

Top Hedge Funds Holding ATAI

Centerbook Partners holds 707.37K shares of ATAI, changed -9.37% as of Mar 31, 2026.
Orbimed Advisors holds 347.00K shares of ATAI, changed +0.00% as of Mar 31, 2026.

Latest ATAI News

Jefferies Highlights H2 2026 Pivotal Readouts in AtaiBeckley Pipeline — May 13, 2026
AtaiBeckley Sets Q2 2026 Phase 3 Launch for MDMA Depression Therapy — May 12, 2026
AtaiBeckley Gets $209.9M Runway, Begins BPL-003 Phase 3, Eyes Q4 VLS-01 Data — May 12, 2026
AtaiBeckley Wins OVID Health Silver Award and Secures FDA Priority Review Voucher — Apr 27, 2026
Atai Life Sciences Gains as Trump Fast-Tracks Psilocybin and MDMA Therapies — Apr 20, 2026

Recent ATAI Insider Trades

Craig Kevin James sold 42.58K (~$212.90K) on Apr 20, 2026.
Craig Kevin James sold 100.00K (~$355.00K) on Mar 20, 2026.
Feilding-Mellen Cosmo sold 39.59K (~$154.38K) on Jan 2, 2026.

ATAI Analyst Consensus

11 analysts cover ATAI: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.90.

Common questions about ATAI

Who owns ATAI stock?: Hedge funds tracked by Rallies that own ATAI include Centerbook Partners and Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for AtaiBeckley Inc. Common Stock.
Does Rallies show 13F holders for ATAI?: Yes. Rallies tracks hedge fund and 13F ownership data for ATAI, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ATAI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ATAI. It does not provide personalized investment advice.